The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial) as well as acute bradycardia independent of changes in bl...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/08570c9c255342e7a483aa39d2774669 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:08570c9c255342e7a483aa39d2774669 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:08570c9c255342e7a483aa39d27746692021-11-18T08:03:15ZThe clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.1932-620310.1371/journal.pone.0052985https://doaj.org/article/08570c9c255342e7a483aa39d27746692012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23285242/?tool=EBIhttps://doaj.org/toc/1932-6203Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial) as well as acute bradycardia independent of changes in blood pressure. However, the precise receptor subtypes responsible is controversial, likely dependent upon the cardiovascular response in question (e.g. bradycardia, hypertension), and perhaps even species-dependent since functional differences in rodent, rabbit, and human have been suggested. Thus, we characterized the S1P receptor subtype specificity for each compound in vitro and, in vivo, the cardiovascular effects of FTY720 and the more selective S1P₁,₅ agonist, BAF312, were tested during acute i.v. infusion in anesthetized rats and after oral administration for 10 days in telemetry-instrumented conscious rats. Acute i.v. infusion of FTY720 (0.1, 0.3, 1.0 mg/kg/20 min) or BAF312 (0.5, 1.5, 5.0 mg/kg/20 min) elicited acute bradycardia in anesthetized rats demonstrating an S1P₁ mediated mechanism-of-action. However, while FTY720 (0.5, 1.5, 5.0 mg/kg/d) elicited dose-dependent hypertension after multiple days of oral administration in rat at clinically relevant plasma concentrations (24-hr mean blood pressure = 8.4, 12.8, 16.2 mmHg above baseline vs. 3 mmHg in vehicle controls), BAF312 (0.3, 3.0, 30.0 mg/kg/d) had no significant effect on blood pressure at any dose tested suggesting that hypertension produced by FTY720 is mediated S1P₃ receptors. In summary, in vitro selectivity results in combination with studies performed in anesthetized and conscious rats administered two clinically tested S1P agonists, FTY720 or BAF312, suggest that S1P₁ receptors mediate bradycardia while hypertension is mediated by S1P₃ receptor activation.Ryan M FryerAkalushi MuthukumaranaPaul C HarrisonSuzanne Nodop MazurekRong Rhonda ChenKyle E HarringtonRoger M DinalloJoshua C HoranLori PatnaudeLouise K ModisGlenn A ReinhartPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e52985 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ryan M Fryer Akalushi Muthukumarana Paul C Harrison Suzanne Nodop Mazurek Rong Rhonda Chen Kyle E Harrington Roger M Dinallo Joshua C Horan Lori Patnaude Louise K Modis Glenn A Reinhart The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| description |
Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial) as well as acute bradycardia independent of changes in blood pressure. However, the precise receptor subtypes responsible is controversial, likely dependent upon the cardiovascular response in question (e.g. bradycardia, hypertension), and perhaps even species-dependent since functional differences in rodent, rabbit, and human have been suggested. Thus, we characterized the S1P receptor subtype specificity for each compound in vitro and, in vivo, the cardiovascular effects of FTY720 and the more selective S1P₁,₅ agonist, BAF312, were tested during acute i.v. infusion in anesthetized rats and after oral administration for 10 days in telemetry-instrumented conscious rats. Acute i.v. infusion of FTY720 (0.1, 0.3, 1.0 mg/kg/20 min) or BAF312 (0.5, 1.5, 5.0 mg/kg/20 min) elicited acute bradycardia in anesthetized rats demonstrating an S1P₁ mediated mechanism-of-action. However, while FTY720 (0.5, 1.5, 5.0 mg/kg/d) elicited dose-dependent hypertension after multiple days of oral administration in rat at clinically relevant plasma concentrations (24-hr mean blood pressure = 8.4, 12.8, 16.2 mmHg above baseline vs. 3 mmHg in vehicle controls), BAF312 (0.3, 3.0, 30.0 mg/kg/d) had no significant effect on blood pressure at any dose tested suggesting that hypertension produced by FTY720 is mediated S1P₃ receptors. In summary, in vitro selectivity results in combination with studies performed in anesthetized and conscious rats administered two clinically tested S1P agonists, FTY720 or BAF312, suggest that S1P₁ receptors mediate bradycardia while hypertension is mediated by S1P₃ receptor activation. |
| format |
article |
| author |
Ryan M Fryer Akalushi Muthukumarana Paul C Harrison Suzanne Nodop Mazurek Rong Rhonda Chen Kyle E Harrington Roger M Dinallo Joshua C Horan Lori Patnaude Louise K Modis Glenn A Reinhart |
| author_facet |
Ryan M Fryer Akalushi Muthukumarana Paul C Harrison Suzanne Nodop Mazurek Rong Rhonda Chen Kyle E Harrington Roger M Dinallo Joshua C Horan Lori Patnaude Louise K Modis Glenn A Reinhart |
| author_sort |
Ryan M Fryer |
| title |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| title_short |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| title_full |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| title_fullStr |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| title_full_unstemmed |
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. |
| title_sort |
clinically-tested s1p receptor agonists, fty720 and baf312, demonstrate subtype-specific bradycardia (s1p₁) and hypertension (s1p₃) in rat. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/08570c9c255342e7a483aa39d2774669 |
| work_keys_str_mv |
AT ryanmfryer theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT akalushimuthukumarana theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT paulcharrison theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT suzannenodopmazurek theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT rongrhondachen theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT kyleeharrington theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT rogermdinallo theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT joshuachoran theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT loripatnaude theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT louisekmodis theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT glennareinhart theclinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT ryanmfryer clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT akalushimuthukumarana clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT paulcharrison clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT suzannenodopmazurek clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT rongrhondachen clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT kyleeharrington clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT rogermdinallo clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT joshuachoran clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT loripatnaude clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT louisekmodis clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat AT glennareinhart clinicallytesteds1preceptoragonistsfty720andbaf312demonstratesubtypespecificbradycardias1p1andhypertensions1p3inrat |
| _version_ |
1718422585476120576 |